Last reviewed · How we verify
Panitumumab and CPT-11 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Panitumumab and CPT-11 (Panitumumab and CPT-11) — Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Panitumumab and CPT-11 TARGET | Panitumumab and CPT-11 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Panitumumab and CPT-11 CI watch — RSS
- Panitumumab and CPT-11 CI watch — Atom
- Panitumumab and CPT-11 CI watch — JSON
- Panitumumab and CPT-11 alone — RSS
Cite this brief
Drug Landscape (2026). Panitumumab and CPT-11 — Competitive Intelligence Brief. https://druglandscape.com/ci/panitumumab-and-cpt-11. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab